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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
Folate 
Folic acid, an essential water-soluble B vitamin also known as B9, was first discovered in 
the 1940’s. The discovery came to light after the finding that a yeast extract corrected macrocytic 
anemia in pregnant women[1]. Most bacteria, yeast and plants can synthesize folates; however, 
animals require folate intake through the diet or through supplementation. Folate refers to 
compounds that include natural folates and folic acid, with folic acid (FA) referring to the fully 
oxidized form[1]. Folic acid, otherwise known as pteroylglutamic acid, was first extracted from 
spinach in 1941[2]. Chemical synthesis of folic acid first took place in 1943 by combining a 
pteridine ring, paraminobenzoic acid and glutamic acid[3]. Folate is essential for growth, 
homeostasis, and plays a critical role in cellular one carbon metabolism. Folate is involved in 
maintaining genomic integrity by regulating gene expression through methylation as well as purine 
and pyrimidine biosynthesis needed for repair and replication. Folate is also involved in amino 
acid metabolism, regeneration of the methyl donor S-adenosyl methionine, the antioxidant 
glutathione, as well as various critical cellular functions [4].  Folate deficiency is implicated in the 
pathogenesis of multiple diseases and conditions such as anemia, cardiovascular disease, neural 
tube defects, neurodegenerative diseases, cancer, and more [5]. Natural folates are found in 
adequate quantities in green leafy vegetables as well as legumes, fruits, yeast, and cereals. Animal 
food sources contain higher amounts of folates especially in liver and kidney [1].  
Absorption  
Absorption of folate from the diet occurs mainly in the proximal small intestine [1]. 
However, recent studies suggest that a significant amount of folate can be absorbed in the colon[6].  




folate carriers (RFC) [1]. RFC is a membrane spanning transport protein that is necessary for the 
transport of folates. Some mutations of the gene encoding RFC can lead to alteration of folate and 
homocysteine levels [7]. The bioavailability of folates is dependent on multiple factors including 
dietary folate content, food sources and preparation methods. Various host factors such as 
mutations in the transporters or inflammatory conditions can limit absorption [1]. Folate absorption 
can be reduced through passage and destruction in the acidic environment of the stomach. 
Surviving folate must be reduced form the polyglutamate form to monoglutamate by folate 
conjugase to be absorbed. It is then converted back to the polyglutamate form and stored in the 







Folate refers to a diverse array of biological molecules that serve as cofactors in one carbon 
transfer and metabolism. Natural folates in the diet and in the body are found predominantly in the 
reduced form commonly as 5-methyl-THF [8]. Folic acid, a synthetic folate, must be reduced to 
dihydrofolate then further reduced to tetrahydrofolate (THF) by dihydrofolate reductase before 
entering the folate cycle. THF is the biologically active form of folate and serves as the starting 
point for one carbon transfer. THF picks up one carbon units from the conversion of serine to 
glycine catalyzed by the methylentetrahydrofolate dehydrogenase (MTHFD) with the vitamin B6 
serving as a cofactor forming N5-N10-methylene-THF. As THF picks up the carbon units it then 
can be interconverted between various oxidative states leading to distinct metabolic outcomes. N5-
N10-methylene THF provides carbon units to thymidylate synthase converting deoxyuridine 
monophosphate (dUMP) to deoxythymidine monophosphate (dTMP). Folate plays an essential 
role as a cofactor in the de novo biosynthesis of purines, thus maintaining DNA integrity during 
DNA synthesis, replication, and repair.  N5-N10-methylene-THF is converted to10-formyl-THF, 
the most oxidized form of folate used in the de novo synthesis of purines, while 5-methyl-THF is 
used in the re-methylation of homocysteine to form methionine, the precursor of S-
adenosylmethionine (SAM). SAM is involved in various biological methylations, most 
importantly the methylation of DNA and histones and epigenetic imprinting [9]. SAM is converted 
back to s-adenosylhomocysteine (SAH) and back to homocysteine. Due to the critical function of 
SAM, the SAM/SAH ratio is tightly controlled via numerous metabolic mechanisms and feedback 
loops. Dietary factors such as folate and methionine availability can affect SAM/SAH ratio leading 
to epigenetic alterations. Homocysteine, long considered to be a marker for various disease 




Homocysteine undergoes irreversible degradation to cysteine and ultimately forming the 
antioxidant glutathione, an important regulator of cellular redox homeostasis[9].  
Folate and neural tube defects 
In 1998 the FDA mandated the addition of folic acid (FA) to all enriched cereal grain foods 
in order to reduce the incidence of neural tube defects in the offspring of women of childbearing 
age [10]. Folate rose to prominence after evidence for interventional trials and observational 
studies revealed that periconceptual folate supplementation protected against neural tube defects 
(NTD) [5]. This revelation led policymakers, the US health service, and the institute of medicine 
to recommend a daily intake of 400 ug folic acid to all women of childbearing age [5]. Soon after, 
the FDA mandated the fortification of all flour and uncooked cereal-grain products in the United 
States with 140 ug/100g of folic acid by 1998 [11], [12]. Similar recommendations were passed in 
Canada, Chile and Western Australia [5]. 
Argument for fortification 
Folate supplementation was seen as safe and beneficial for disease prevention [13]. This 
argument was based on abundance of evidence from various studies linking folate deficiency to 
various diseases including, anemia, cardiovascular disease, neurological disease, cancer, neural 
tube defects (NTD), and low birth weight [13], [14]. Prior to FA fortification, targeted 
supplementation with FA in women at risk and of childbearing age failed to yield encouraging 
results due to failure to abide to the vitamin regimen. Despite the presence of massive education 
and awareness programs, the results did not translate into behavioral changes in the participants 
[5]. The risk of non-compliance with the recommendations was augmented by the fact that the 
neural tube closes during the fourth week of gestation, a time most women are unaware they are 




benefits in the general population encouraged health policy advocates to push for generalized folic 
acid fortification [5].  
Effectiveness of fortification 
The goal of the fortification program initiated in 1998 by the FDA was to increase daily 
intake of folates by about 100 ug/d while maintaining total intake under 1000 ug/d (safe upper 
limit of daily intake) [10]. However, recent studies revealed the predicted increase in folic acid 
from fortified food to be much higher (215-240 ug/d) [10]. Fortification lead to an equivalent 
decrease of homocysteine [13]. The effect of the fortification on NTD was significant as studies 
from the US and Canada showed a reduction of 15-50% in the incidence of NTD [13]. The 
dramatic decrease in NTD, however, cannot be solely attributed to the increase in folate levels due 
to fortification. Other factors such as improved nutrition and prenatal care had been playing a role 
in the steady decrease of NTD even before fortification began[5]. 
Controversies  
For every neural tube defect prevention, several hundred thousand people are exposed to 
increased levels and intake of folic acid [15]. Animal studies show that a diet high in folate can 
affect DNA and histone methylation leading to epigenetic changes that can be inherited, affecting 
successive future generations[15]. Folic acid supplementation can lead to elevated levels of 
naturally occurring folates as well as unmetabolized folic acid in the blood [15]. There is currently 
a raging controversy among researchers on the risk vs benefit of supplementing the whole 
population with high levels of synthetic folates to reduce the risk of comparatively small number 
of neural tube defects[15]. In the United kingdom, it is estimated that for every neural tube defect 
prevention, there are up to three-quarter million people exposed to extra folic acid with similar 




that folate supplementation reduces cardiovascular and stroke risk [13]. The controversies 
surrounding FA has led many countries into adopting a more cautious approach to 
supplementation[16]. 
Is Folate harmful? 
Folate was deemed generally safe with almost no toxicities [5], however, its use in food 
fortification is controversial. High folate intake can mask vitamin B-12 deficiency, a condition 
with relatively high prevalence among the geriatric population [17]. Some argue that even 
moderate intake is capable of producing a masking effect, prompting several countries to delay or 
reject adopting folate fortification mandates [5]. FA intake raises concerns of negative adverse 
effects in various subpopulation groups that do not stand to benefit from supplementation [5]. 
Safety Data for long term exposure to high dose synthetic folates do not exist and is not well 
understood [5]. There is mounting evidence that FA may promote the growth and progression of 
existing preneoplastic or neoplastic lesions [18]. An increasing percentage of the population is 
exposed to folates in levels that exceeds the upper safety limit caused by fortification and 
additional supplementation [19]. Folate supplementation can interfere with and reduce the 
effectiveness of antifolate based chemotherapy [19]. FA can also interact with prescription drugs 
including seizure medications, anti-inflammatory therapies, and malaria medications[15][5]. Other 
evidence points to FA supplementation causing genetic instability through epigenetic changes and 
selection of disease alleles [20]. High levels of folic acid have been linked to an immune 
weakening effect by decreasing natural killer cell cytotoxicity[15]. Furthermore, there is evidence 
that folate supplementation to pregnant women can lead to increased risk of insulin resistance and 





Folate and cancer 
The link between folate and cancer was established shortly after folic acid discovery and 
extraction [1]. Folate impact on cancer is complex and at times contradictory [18], [19]. After FA 
was discovered in the 1940’s, based on limited evidence, researchers attempted to administer FA 
to children with leukemia leading to accelerated progression and poor outcomes [13]. Researchers 
then learned that the proliferation of leukemia cells is dependent on the availability of the 
tetrahydrofolate metabolites leading to the successful use of folate antagonists such as aminopterin 
to produce full remission of children with acute leukemia [13]. Conversely, evidence from a 
number of studies suggest that folate deficiency can increase the risk of cancer in normal tissues 
while adequate folate levels has a protective effect on the risk of developing malignancies of 
various tissues [13][21].  
There are multiple theories on how folate deficiency can induce carcinogenesis. These 
range from folate deficiency causing DNA strand breaks due to uracil misincorporation, alteration 
of DNA methylation patterns and gene expression, genomic instability and chromosomal 
aberrations [22]–[24]. Others point to impaired DNA repair pathways under folate deficiency, thus 
reducing DNA damage threshold and increasing the risk of transformation and mutations with or 
without the addition of DNA damage or insult [25]–[28].   
More recently, FA fortification was linked to a significant decrease in neuroblastoma 
among children, however no change was detected in the incidence of infant acute lymphoblastic 
leukemia and hepatoblastoma [13]. A case control study from Germany shows that mothers 
supplementing with vitamins containing FA resulted in a decreased risk of non-Hodgkin’s 
lymphoma and some types of leukemia in their offspring, however, there was an increased risk of 




showed a 70% increase in all cancer mortality and a doubling of breast cancer mortality risk[30]. 
Kim et al. observed that FA fortification in women who are pregnant or of childbearing age can 
potentially reduce the risk of certain childhood cancers in the offspring, however, this comes at 
the risk of promoting the growth and progression of undiagnosed, preneoplastic or neoplastic 
lesions [19]. 
Folate and colorectal cancer 
Evidence from recent meta-analyses suggest a significant reduction of adenomas and 
colorectal cancer (CRC) when comparing subjects of the highest folate status with the lowest [13]. 
The Nurse’s Health Study showed a 75% reduction in colorectal cancer in women taking 
multivitamins with folate [31]. The ASPIRIN/FOLATE polyp prevention study published in 2003 
reported that FA supplementation at 1 mg/d had no effect on the recurrence of adenomas. However, 
there was a 67% increase in highly malignant advanced lesions at the second follow up [32]. 
Furthermore, there was a significant increase of other malignancies such as prostate cancer in the 
folate supplemented group. Despite a decrease in homocysteine among the FA subjects, 
cardiovascular risk was not decreased among the FA supplemented group [32].  
Animal studies reveal a dual modulating effect of folate on colorectal cancer whereby the 
timing and dosage of folate can have contrasting results [33]. The results show that folate 
deficiency increases the risk of transformation, while modest supplementation reduces cancer risk, 
and high or supraphysiological doses increase it [13]. Furthermore there is evidence that folate 
supplementation can increase CRC risk after the establishment of microscopic neoplastic foci [5]. 
A possible explanation to this modulation is that folate deficiency in normal tissues can lead to 
uracil misincorporation due to the decrease in thymidylate synthesis causing DNA strand breaks, 




DNA methylation due to the possible decrease of S-adenosylmethionine leading to DNA 
methylation abnormalities [13]. A folate adequate diet is expected to correct these aberrations 
leading to a decrease in cancer risk. However, in preneoplastic or fully transformed lesions, folate 
deficiency can inhibit the growth requirements of a rapidly proliferating tissue, leading to 
decreased tumor growth and progression. At the same time, FA supplementation can provide the 
tumor with nucleotides leading to faster growth [34]. As evident from several studies, FA 
supplementation to individuals who might harbor microscopic undiagnosed preneoplastic lesions 
can lead to adverse outcomes by fueling cancer growth [32]. It is estimated that 25-50% of people 
in the US and Canada may carry asymptomatic adenomas by the age of 50 with the prevalence 
increasing with age [13]. Recent large studies reported a nonsignificant trend in total and colorectal 
cancer risk due to FA supplementation [13]. In the post fortification era, it is estimated that folate 
fortification has added about 200 ug/d FA through enriched products leading to a total intake of 
approximately 400 ug/day for non-supplement users and over 800 ug/day in individuals taking 
additional supplementation [13]. Other studies pointed out that these are likely to be 
underestimates indicating that a significant percentage of the population has high serum 
folates[13]. Analysis performed my Mason et al. shows that the United States and Canada had a 
reversal in the downward trend in colorectal cancer shortly after the FA mandate. The authors 
hypothesized that FA is wholly or partly responsible for the observed reversal in the trend, 





 CRC incidence Post Fortification by Mason et al.[35] 
Folate and mTOR 
Our early work with folate looked at the impact of folate deficiency on the initiation and 
progression of colon cancer in a polymerase  haploinsufficient (-pol+/-) mouse model. We had 
originally established that folate restriction negatively impacts DNA base excision repair (BER), 
a critical pathway that is required to repair DNA oxidative damage and uracil misincorporation, 
by regulating the expression of its rate limiting enzyme -pol [36], [37]. We then hypothesized 
that folate restriction in addition to -pol haploinsufficiency will lead to an increased formation of 




(DMH). To our surprise, folate restriction in these animals conferred protection under these 
conditions (fig1.1) [38]. Analysis of tissue samples via BrdU and TUNEL assays revealed a 
decrease in proliferation and an increase in apoptosis in the colon of folate restricted animals [38]. 
We became interested in understanding how folate restriction (FR) can be protective in our colon 
cancer models and if that protection can persist under different conditions and genetic 
backgrounds. Analysis of the literature showed that other labs were observing that reduced dietary 
folate can confer protection against cancer as well as reducing inflammatory bowel disease in 
various lab rodent models [39]–[41].  We were looking for a missing link that can integrate signals 
from one carbon metabolism and affect proliferation, apoptosis and cancer, explaining our 
findings. Our breakthrough came about when analyzing microarray expression data comparing 
folate restricted animals to folate adequate. We saw that folate restriction significantly altered the 
expression of genes in the mTOR pathway. Analysis of plasma amino acid levels provided us with 
further evidence of the modulating effect of FR on various amino acids, specifically methionine, 
isoleucine and leucine. As mTOR is central to the pathways we were investigating, we were 
compelled to provide a mechanistic analysis of the effect of folate restriction on mTOR and 
colorectal cancer.  
The mammalian target of rapamycin also known as the mechanistic target of rapamycin 
mTOR is a conserved serine/threonine protein kinase that integrates signals such as growth factors, 
amino acids, energy levels, and nutrient availability to modulate cell growth, proliferation, 
autophagy, and metabolism. mTOR is found in 2 distinct complexes mTORC1 and mTORC2. 
mTORC1 is rapamycin sensitive and is regulated by multiple upstream signals such as growth 
factors, amino acid availability, stress and hypoxia, and energy availability [42], [43]. mTORC2 




complex1. mTOR became the focus of intensive research in recent years as this signaling pathway 
has been altered in various conditions such as cancer, diabetes, and aging [44]. More recently, 
mTOR has been found to be modulated by perturbation in one carbon metabolism and more 
specifically folate availability [45]. Folate was shown to activate the mTOR pathway via activation 
of the AKT pathway, phosphorylating mTOR and the downstream targets p70S6k1 and 4E-BP1 
[46]. Furthermore, mTOR was found to be directly linked to one carbon metabolism. Researchers 
reported that mTORC1 could control the mitochondrial tetrahydrofolate cycle and induce purine 
synthesis as well as stimulate the generation of SAM [47], [48].  Rosario et al. observed that 
placing mice on folate free diet for 6 weeks produced marked inhibition of mTORC1 and mTORC2 
in various tissues. Further inhibition of downstream targets of both complexes was also observed 
as well as decreased activity and expression of the amino acid transporters solute carrier (SLC) 
[49]. In other research, Rosario et al. suggested that mTOR may utilize the same amino acids 
sensing mechanism for folate sensing [50]. Similar findings linking folate levels to mTOR 
signaling, and amino acid transporter activity were confirmed in baboons and humans [49]–[51]. 
Furthermore, Rosario et al. provided evidence that mTOR can directly regulate folate transporters 
trafficking thus regulating cellular folate uptake [52]. 






Our lab was interested in understanding how the timing and duration of folate restriction 
impacts colon carcinogenesis. Our initial studies in the  haploinsufficient (-pol+/-) mouse model 
yielded the surprising result of folate restriction conferring protection against colon cancer 
initiation as seen in the reduced numbers of ACF (figure 1.1). To further understand how a folate 
depleted diet impacts folate levels over time, we conducted a study with semi synthetic AIN93G-
purified isoenergetic diet. Chow diet was not considered suitable for folate studies as it can contain 
variable amounts of folates that range from 2-15mg/kg of diet. Our folate adequate semi synthetic 




Plasma folate decreased in the folate depleted (FD) group by the 3rd day on the diet and no further 
decrease was observed after the first week (figure 1.2). On average we observed a 90% decrease 
in plasma folate in animals fed FD diets (figure 1.3). The experiment was continued for 12 weeks 
and the animals did not exhibit any signs of anemia or pathologies. As a result, we termed this 
condition folate restriction rather than folate deficiency. Further pilot studies were conducted to 
study the effect of long-term folate restriction. After placing the animals on FD diets for 16 months, 
the animals did not display any signs of anemia and looked overall healthier than their FA 
counterparts. In a separate study, when we exposed long-term FD diet mice to the carcinogen 
dimethylhydrazine (DMH), the animals developed less ACF than the mice fed FA diet. This was 
in contradiction to our earlier studies and most published folate restriction studies[53]. It is 
important to point out that a review of the literature reveals that most studies investigating the 
effect of folate restriction on carcinogenesis place the animals on folate depleted diets for a 
relatively short duration before introducing the carcinogenic insult [54]. This short period of 
depletion does not allow the animals a chance to acclimate to folate restriction. To confirm the 
results, a larger experiment was designed to study the differential effect of the timing and duration 
of folate restriction on mice colon carcinogenesis. The animals were fed either a FA (2 mg FA/kg 
diet) diet, FR (0 mg FA/kg diet), or FA/FR (7 weeks on FA diet then 1 week on FR diet) for a total 
of 8 weeks. Animals were randomly chosen, exposed to DMH, and later sacrificed. As expected, 
we saw a significant (90%) decrease in folate levels in both the short term (FA/FR) and long term 
(FR) folate restricted groups as compared to controls (figure1.4). Remarkably, long term folate 
restriction conferred protection on animals that acclimated to folate restriction for 8 weeks. We 
observed that placing the animals on a folate restricted diet for one-week (FA/FR) before initiating 




animals. This finding was consistent with what is reported in the literature and our previous studies. 
However, animals on long term Folate restriction (FR) had less ACF in the colon compared to 
FA/FR animals (figure 1.5). This observation held true despite measured serum and tissue folate 
levels being comparably lower in both folate restricted groups (FA/FR) and (FR) compared to FA. 
We were faced with a paradox that begets the question: is all folate restriction disadvantageous 
with respect to CRC? And, how can the duration and the timing of folate restriction differentially 
impact the critical pathways that run amok in cancer? Furthermore, what other confounders are 
present in the standard models and study designs further skewing the results and leading to our 
incomplete understanding of the science? 
To answer these questions, I began by examining the studies used to assess the effect of 
folate restriction on colon carcinogenesis. Many studies including ours resorted to the use of the 
antibiotic succinylsulfathiazole (SST) to reduce folate producing bacteria in the gut of the 
animals[36], [38]. SST radically alters the composition of the gut microbiome. We wondered if 
the use of SST can introduce a confounding element to our studies. The first part of my analysis 
addresses the potential of this antibiotic to alter critical pathways known to be affected by folate 
status such as mTOR, and oxidative stress. In this study, I analyzed the effect of SST on folate 
levels in folate adequate c57Bl/6 male mice fed folate supplemented diet. I did not observe any 
significant difference on growth and weight gain at 21 weeks. SST did not significantly affect 
folate levels in the plasma, liver and colon tissues of folate adequate mice, however it did alter 
energy metabolism and expression of key proteins in the mTOR signaling pathway in the liver. 
This research helps shed light on a possible confounding element when using SST to study folate 




In the second part of the analysis, I will address the findings that the timing and the duration 
of folate restriction has a differential effect on colon carcinogenesis. As stated previously, I 
observed that long term folate restriction (FR) conferred protection to animals compared to short 
term (FA/FR). My research will attempt to elucidate a mechanistic analysis of how short- and long-
term folate restriction differentially impact the critical pathway of mTOR, upstream regulators and 
downstream targets as well select gene expression analysis. This analysis will be done on animals 




























Figure 1.1: The effect of folate restriction on colon carcinogenesis in β-pol haploinsufficient mice. 
Figure adapted from publication by Lucente et al [38]. WT and β-pol+/− C57BL/6 mice were fed 
either a folate-adequate (2 mg FA/kg diet) or a folate-deficient (0 mg FA/kg diet) diet. After 1 
week on the respective diets, animals were randomly chosen and were injected with 30 mg/kg 
body weight of DMH for 6 weeks. Six weeks after the final injection, animals were sacrificed by 
CO2 asphyxiation. The abdominal cavity was opened, and the colon was excised, rinsed with cold 
phosphate-buffered saline, cut longitudinally, and fixed flat overnight in 10% neutral buffered 
formalin. On the next day, the colonic crypts were stained with 2 g/liter of methylene blue in 
phosphate-buffered saline for 5 min. The number of ACF was determined by light microscopy at 
×10 magnification in a blinded manner. Bars indicate S.E. (n=6). Different letters indicate 



















Figure 1.2: The effect dietary folate restriction on plasma folate levels at various timepoints. 
C57BL/6 mice were fed either a folate adequate (FA) or folate depleted (FD) AIN93G-purified 
isoenergetic diet (Dyets, Inc., Lehigh Valley, PA) as previously described [32]. The FA group 
received a folate adequate diet containing 2 mg of folic acid/kg diet. The FD group received a 
folate-deficient diet containing 0 mg of folic acid/kg diet. The animals remained on their respective 
diets for the duration of the study. Blood was drawn from the capillary of the eye at various time 
points, and folate levels were analyzed using the lactobacillus casei microbiological assay [33]. 
(FA) represents the average value of folate levels for folate adequate fed mice normalized to 100%. 
The FD bars represent the average values of blood folate levels expressed as a percentage of FA 
levels at various time points. (n=6 per group). Bars represent S.E.M. Different letters indicate 


















Figure 1.3: The effect of folate in the diet on plasma folate levels in C57BL/6 mice.  
The animals were fed either a folate adequate (FA) or folate depleted (FD) AIN93G-purified 
isoenergetic diet (Dyets, Inc., Lehigh Valley, PA). The FA group received a folate adequate diet 
containing 2 mg of folic acid/kg diet. The FD group received a folate-deficient diet containing 0 
mg of folic acid/kg diet. The animals remained on their respective diets for 12 weeks after which 
they were sacrificed. Plasma was collected and folate levels were analyzed using a lactobacillus 










CHAPTER 2: SUCCINYLSULFATHIAZOLE MODULATES mTOR SIGNALING 
Introduction  
The gut microbiome is a complex and diverse array of microorganisms that colonizes the 
digestive system. The gut microbiome of humans and other mammals have been extensively 
studied due to its profound effect on the health and disease of the host. Perturbations of the gut 
microbiome has been linked to various disease etiologies, including: metabolic diseases such as 
obesity and type 2 diabetes, autoimmune disorders, inflammation, allergies, cancer, and more[55]–
[63]. The gut microbiota is responsible for producing a plethora of compounds and signaling 
molecules that facilitates the complex interactions with its host. These compounds include: 
branched chain fatty acids, organic acids, menaquinones (vitamin K), and some B vitamins[64], 
[65]. Specifically, the ability of certain bacteria in the gut to synthetize large amounts of folates is 
well documented[66], [67]. Others have shown that bacterial folate is easily absorbed and 
incorporated into the host folate stores in various tissues[6], [68]–[71]. The amount of folates 
produced by a healthy gut flora, specifically through fermentation in the large intestine, is diet 
dependent. In fact, diets rich in fermentable fibers have been shown to increase folate levels and 
decrease homocysteine in rats, while no effect was observed with non-fermentable fiber 
supplemented diets[72].  
Other manipulation of the diet, such as the addition of antibiotics, can yield drastic changes 
to the gut microbiome[73]–[76]. Specifically, the addition of 1% succinylsulfathiazole (SST), a 
long-acting sulfonamide, can produce large shifts in the composition of the gut flora and its ability 
to synthetize folate[77], [78]. Succinylsulfathiazole is characterized by its poor absorption and 
localized antibacterial activity that is primarily limited to the gut[79]. It was used in the 1940s as 
gut antiseptic to lower the bacterial load and prevent infections after gut surgeries[77], [80], [81]. 




through competitive inhibition with P-aminobenzoic acid (PABA)[82]. SST persists in the gut 
much longer than absorbable antibiotics and has no known systemic toxicities[83]. It is hydrolyzed 
slowly in the large intestines by bacterial esterases to the active form sulfathiazole[79]. The effect 
of SST on gut microbial density and folate production is well documented in earlier studies dating 
to the 1940’s[77], [80], [81]. Since then, SST has been replaced clinically by more efficacious and 
potent antibiotics. However, researchers have used it extensively in various studies to reduce or 
limit the folate producing bacteria in various lab models[36], [84]–[86].  
In our studies, we have used SST along with dietary folate restriction to study the impact 
of folate depletion on colon cancer initiation[87]. Specifically, we were concerned that the use of 
SST to induce a folate deficient status in rodents can modulate some of the same pathways that are 
affected by folate depletion. In the present study, we were interested in examining the long-term 
effects of SST in the liver of C57BL6 mice fed folate supplemented diets. We analyzed the Impact 
of SST on folate levels in serum, colon, and Liver tissues. We were specifically interested in 
investigating the effect of the antibiotic on the mTOR signaling pathway, a major growth regulator 
that converges signals form growth factors, amino acids, glucose, stress, and energy levels, and 
impacts cellular growth, autophagy, and proliferation.  
Experimental Procedures 
Animals- c57Bl/6 male specific pathogen free mice were purchased from Charles Rivers at 6 weeks 
of age (n=3). Animals were maintained in accordance with NIH guidelines for the use and care of 
laboratory animals. The Animal protocol was approved by the Wayne State University Animal 
Investigation Committee. They were fed the standard mouse chow and water ad libitum and were 
maintained on a 12-hr light/dark cycle until the start of the experiment. Mice were anesthetized in 




liver tissue. Blood was obtained by cardiac puncture, centrifuged, and the serum separated.  The 
harvested liver was flash frozen and stored in liquid nitrogen. 
Diets- At 4 months of age, mice were randomly assigned to two dietary groups and fed AIN93G-
purified isoenergetic diets (Dyets, Inc., Lehigh Valley, PA)[88]. Diets were stored at -20°C. The 
control group received a folate adequate diet (2mg FA/kg diet for 21 weeks). The experimental 
group received a folate adequate diet supplemented with 1% succinyl sulfathiazole (2mg FA/kg 
diet + 1% succinyl sulfathiazole for 21 weeks).  
Folate Assay- Serum, liver and colon mucosa were collected upon sacrifice. Folate was measured 
using the Lactobacillus casei microbiological assay of folic acid derivatives as described by Horne 
et. Al[89]. Briefly, growth response of lactobacillus casei to folate availability was measured at 
OD 600 nm. A standard curve was used to calculate folate concentrations. Folate levels are 
expressed as nmol/g.  
Isolation of Whole cell extract- Whole cell extracts were isolated using RIPA buffer. Briefly, 50 
mg of liver tissue was homogenized using RIPA buffer (1% Igepal, 0.5% Sodium deoxycholate, 
0.1% SDS, 1X PBS) combined with HALT protease inhibitor cocktail (Thermo Fisher). Whole 
cell extracts collected were stored at -80°C for further analysis.  
Western Blot Analysis- Protein expression analysis was performed using the V3 western blot 
system from Bio-Rad. 50 μg of protein was loaded onto criterion TGX stain free precast Gels (Bio-
Rad, Hercules, CA). Gels were imaged using chemidoc XRS+ system then wet transferred onto 
nitrocellulose membranes. Membranes and Gels were imaged to verify complete transfer. 
Manufacturer recommended dilutions of anti-sera developed against various anti-bodies (cell 
signaling) were used to detect proteins of interest followed by incubation with HRP-conjugated 




quantified using chemidoc XRS+ imager and Image lab software (Bio-Rad, Hercules, CA) after 
incubation in SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology, 
Rockford, IL). Data are expressed as adjusted band volume normalized to total lane proteins. 
Phosphorylated forms of proteins were normalized to total and expressed as ratio. 
Gene expression profiling- The mRNA expression levels of various genes were quantified using a 
real-time PCR. Total RNA was extracted from liver tissue using RNeasy extraction kit (Qiagen, 
Valencia, CA). First strand cDNA was synthesized from 1μg RNA using random primers and poly-
A primers. Expression of each gene was quantified using real time PCR with specific primers for 
the gene. The gene transcript was normalized to GAPDH. External standards for all genes were 
prepared by subcloning the amplicons, synthesized using the specific primers into PGEM-T easy 
vector. Primer Sequences are listed in Table 2.1.  
ATP Assay- ADP/ATP ratio was assessed using a luciferase based bioluminescent assay kit 
(Abcam). Briefly, 10 mg of liver tissue was quickly homogenized with nucleotide releasing buffer. 
Using a microplate reader, the homogenate was assayed per protocol to determine ATP induced 
luminescence. Then ADP converting enzyme was added and luminescence was further 
determined. Data are expressed at ADP/ATP ratio.  
NAD/NADH Assay- NAD+/NADH was assayed using a fluorometric microplate reader assay 
(Abcam). 20 mg of liver tissue was homogenized in provided lysis buffer and supernatant was 
collected. Total NAD, NAD+ and NADH were assayed per protocol. Fluorescence was measured 





Statistical Analysis- Statistical significance between means was determined using t-test and 
analysis of variance followed by post tukey test wherever appropriate.  P-values less than 0.05 
were considered statistically significant. 
Results 
Antibiotic in the Diet and its Effect on Weight gain, Serum, Liver and Colon Folate Levels: 
The purpose of this study was to analyze the potential confounding effect of antibiotics 
used to induce folate depletion in mouse folate studies. Since antibiotics have been used non-
therapeutically in animal husbandry to promote weight gain and growth[90], we were interested 
in examining the long-term (21 weeks) effect of SST on animal weights. We monitored weight 
gain weekly for the duration of the study, however there was no difference after 21 weeks on the 
diets (Figure 2.1 a). The animals grew normally and did not exhibit any gross anomalies.  We also 
did not observe any differences in food consumption (Figure 2.1 b) between the control and 
experimental groups.  
We were interested in determining whether long term SST alone influences folate levels in 
the animals. As expected, we did not observe any significant difference in tissue specific folate 
levels between animals fed control (folate supplemented) diet and treated (folate supplemented + 
1% SST) diet (Figure 2.1 c). Liver folate levels were highest (control: 48.1 ng/ml, treatment: 53.7 
ng/ml) compared to serum (control: 32.7 ng/ml, treatment: 34.1 ng/ml), and colon folate (control: 
4.2 ng/ml, treatment: 2.8 ng/ml). This is consistent with findings of previous studies. SST is known 
to competitively inhibit folate uptake in the colon due to structural similarities to folic acid, 
however we did not see a significant difference in colon folate levels in the AB treated group. In 




decrease of folate levels in plasma, liver and colon (Figure 2.1 c). Thus, we show here that SST 
alone does not significantly affect liver, serum and colon folate levels.  
Our lab has previously shown that folate depletion provides protection against colon 
carcinogenesis in β-pol haploinsufficient mice[87]. We have also seen that folate status in the diet 
alters expression of genes in mTOR signaling (Figure 2.2); a major nutrient sensing pathway that 
has been implicated in cancer and aging. Since SST is widely used in folate depletion mouse 
studies, it became critical to understand the effect of SST alone on mTOR signaling.  
Antibiotic Effect on the PI3K/AKT/mTOR Signaling Pathway: 
mTOR, mammalian target of rapamycin, is a conserved serine/threonine protein kinase 
downstream of the PI3K/AKT signaling pathway[43]. It is present in two multiprotein complexes 
(mTORC1 and mTORC2) and integrates signals from multiple upstream factors such as insulin, 
hormones, cytokines, growth factors, stress, hypoxia, glucose, energy and amino acid levels 
(Figure 2.3). mTORC1 specifically is a key player in regulating multiple downstream processes 
such as cell growth, proliferation and autophagy[91]. mTOR signaling has been shown to be 
dysregulated in various cancers and is a key target in multiple life extension strategies[44], [92], 
[93]. Since our array data previously showed that mTOR signaling is reduced under FR (Figure 
2.2) it became crucial to determine whether SST has a confounding effect on the expression of 
proteins in this pathway. 
PDK1 (3-phosphoinositide-dependent protein kinase 1) is an upstream activator of 
mTORC1 in the IRS-1/PI3K/AKT pathway. It phosphorylates AKT at the Thr308 residue, 
inhibiting the TSC1/TSC2 complex and activating mTORC1[94]. mTORC2 on the other hand 
phosphorylates AKT (Ser473) as a feedback mechanism activating mTORC1. SST alone 




has no effect on AKT expression (Figure 2.4 b) and significantly decreases phosphorylation of 
mTORC1 at the ser2448 residue (Figure 2.4 c-d).  
We examined the role of SST and its effect on mTORC1 regulation of protein synthesis 
and autophagy (Figure 2.3). The main characterized substrates of mTORC1 in regulating 
translation are S6K1 (ribosomal p70 S6 protein kinase) and 4E-BP1 (eukaryotic initiation factor 
4E-binding protein 1)[94]. In line with decreased mTORC1 expression, we saw that SST 
significantly decreases 4E-BP1 phosphorylation (Figure 2.4 e) but does not influence S6K1 
phosphorylation (Figure 2.4 f). We looked at the effect of SST on the expression of autophagy 
related proteins Beclin, ATG5 and LCIII and we did not observe any differences (Figure 2.4 g-i). 
Observing that SST alters expression of proteins in the PI3K/AKT/mTOR signaling pathway, we 
were interested in understanding whether it alters other upstream regulators of TOR signaling, 
specifically regulators of stress and energy metabolism.  
The effect of SST on upstream regulators of mTOR: 
The mTOR signaling pathway is directly altered in response to hypoxia, DNA damage and 
energy status[91]. REDD1 (regulated in development and DNA damage response 1) is induced 
following exposure to hypoxia, DNA damage and other environmental stresses such as energy 
stress and reactive oxygen species[95], [96]. An increase in REDD1 levels lead to the activation 
of TSC1/TSC2 complex and inhibition of mTORC1 (Figure 2.3). Interestingly, REDD1 protein 
expression in the liver significantly increases in response to SST (Figure 2.5 a), consistent with 
the inhibition of mTOR seen (Figure 2.4 c). 
The mTOR signaling pathway has also been shown to be altered in response to energy 
status[97]. AMPK, a metabolic fuel gauge that detects changes in intracellular AMP/ATP ratio, 




energy stores by switching on pathways that produce ATP and switching off pathways that 
consume ATP[97]. AMPK also enhances SIRT1 activity by increasing cellular levels of NAD+ 
[99]. NAD cycles between the oxidized (NAD+) and reduced forms (NADH), partaking a central 
role in cellular metabolism and energy production. We observed a significant decrease in 
ADP/ATP ratio (Figure 2.5 b) and AMPK phosphorylation (Figure 2.5 c) in response to SST. 
However, we did not see an effect on SIRT1 expression (Figure 2.6) or NAD+/NADH levels 
(Figure 2.5 d) in the SST fed group. Our study sheds light on SST affecting expression of multiple 
regulators of mTOR independent of folate status in the diet. 
Discussion 
Recently, various laboratories began uncovering the complex interactions between the gut 
microbiome and the host [56], [58]–[61], [64], shedding new light on the importance of these 
microorganisms on the overall health. Antibiotic use in laboratory models can introduce significant 
confounding elements to an experiment due in part to the perturbation of the intestinal 
microbiome[74], [75], [100].  
In our current study, the antibiotic alone did not influence serum and liver folate levels. We 
did however see a non-significant decrease in colon folate in the SST group, possibly due to the 
localized effect of the antibiotic on the gut flora. Since SST is used to deplete folate in folate 
restriction studies directly impacting one Carbon metabolism[36], [84]–[86], we were interested 
in looking at the effect of the antibiotic alone on the expression of genes in the transulfuration 
pathway. SST did not have a significant effect on the expression of cystathione-beta-synthase 
(CBS) the rate limiting enzyme in the transulfuration pathway or on the expression of anti-oxidant 




Analysis of cellular energy levels revealed an increase in energy availability (decrease of 
ADP/ATP ratio) in SST fed mice. This was consistent with decreased activation of the cellular 
energy gauge AMPK. Conversely, we did not observe a change in NAD+/NADH ratio consistent 
with SIRT1 mRNA expression.  
Analysis of protein expression of targets in the mTOR signaling pathway revealed 
decreased activation upstream (PDK1), at both phosphorylated residues of mTOR (ser2448, 
ser2481), and at the downstream target (4ebp1). We looked at the expression of a downstream 
target of S6K1 important in cell cycle regulation and proliferation, P16[94], but we did not see any 
significant difference (Figure 2.6).  Interestingly, we saw increased activation of REDD1, an 
inhibitor of mTOR signaling that responds to stress and hypoxia. Paradoxically, increased energy 
levels leading to the inactivation of AMPK did not result in upregulating mTOR. 
Since SST is poorly absorbed, we suspect that the effect we saw is mediated through the 
perturbation of the intestinal microflora, where further research is warranted. Recently, the gut 
microbiome has been linked to complex interactions that affect almost all physiological functions 
including but not limited to metabolism, immunity, inflammation, stress, and cancer [58], [60], 
[61], [79]. This research helps shed light on a possible confounding element when using SST to 











Table 2.1: Primer Sequences 
 
 





GAPDH GCACAGTCAAGGCCGAGA ATGGGGGCATCGGCAGA 
Sirt1 TGATTGGCACCGATCCTCG CCACAGCGTCATATCATCCAG 



























   












Figure 2.1: 1% succinylsulfathiazole (SST) in the diet does not impact weight gain, food intake or 
folate levels in folate adequate c57BL/6 mice.  
a) Average mouse weights at the beginning of the experiment and after 21 weeks on respective 
AIN93G semi synthetic diets (Control= folate adequate diet (2 mg folate/kg diet), Treatment= 
folate adequate diet (2 mg folate/kg diet) + SST). b) Average food consumption at the beginning 
and at the end of the study. c) Folate levels (nmol/g) in the serum, liver and colon of mice fed 
control and treatment diets compared to folate levels in mice fed a folate restricted diet (0 mg 























Figure 2.1: 1% succinylsulfathiazole (SST) in the diet does not impact weight gain, food intake or 






















































Figure 2.2: Summary of the effect of folate restriction on expression of genes in the mTOR 
pathway.  
Data adapted from Lucente et al [38]. Gene expression shown as fold change in β-pol+/- 
DMH/folate restricted and WT/folate restricted compared to WT/folate adequate. differentially 
expressed genes from colon mucosa were analyzed using the Agilent Whole Mouse Genome 
oligonucleotide microarray containing probes for over 41,000 well characterized genes and 
analyzed with Agilent Feature Extraction software, version A.5.1.1. The false discovery rate for 
FDWT was 5.1%, 1.7% for FDWT DMH treated, and 0.39% for FD β-pol+/− DMH-treated 
experimental groups. Gene ontology analysis was performed using the Gene Ontology Tree 
Machine (GOTM) (Bioinformatics, Vanderbilt University). Single gene set analysis was 
performed, where GOTM compares the distribution of single gene sets in each GO category to 
those in an existing reference gene list from the mouse genome, identifying GO categories with 
statistically significant enriched gene numbers as determined by the hypergeometric test (p < 

























































Figure 2.4: Succinylsulfathiazole alters expression of proteins involved in the PI3K/AKT/mTOR 
signaling in the liver of c57BL/6 mice resulting in an overall decreased mTOR signaling. 
Western blot images and quantification of: a-b) phosphorylation of upstream regulators of mTOR 
(PDK-1 (ser241) and AKT(ser473)), c-d) mTOR phosphorylation at ser2448 and ser2481 residues, 
e-f) phosphorylation of downstream targets of mTOR (4ebp1 (thr37/46) and s6k1(thr421/ser424)), 
and g-i) expression of autophagy related proteins (beclin, atg5 and cleaved lc3) in the liver of mice 
fed control and treatment diets. Protein expression analysis was performed using the V3 western 
blot system from Bio-Rad. Mice were placed on respective AIN93G semi synthetic diets for 21 
weeks; Control= folate adequate diet (2 mg folate/kg diet), Treatment= folate adequate diet (2 mg 



































Figure 2.4: Succinylsulfathiazole alters expression of proteins involved in the PI3K/AKT/mTOR 



























Figure 2.5: Effect of SST on upstream regulators of mTOR in the liver of c57BL6 mice. a) Western 
blot image and quantification of REDD1 protein expression, b) ADP/ATP ratio, c) western blot 
image and quantification of AMPK (thr172) protein phosphorylation and d) NAD+/NADH levels. 






















































































Figure 2.6: Effect of SST on relative expression of genes known to be altered by dietary folate 
status in the liver of mice (Treatment: Control).  
Analysis of mRNA levels in liver of FA SST and FA mice. Mice were placed on respective 
AIN93G semi synthetic diets for 21 weeks; Treatment= folate adequate diet (2 mg folate/kg diet) 
+ SST), Control= folate adequate diet (2 mg folate/kg diet). Expression of the genes was 
determined using a real time PCR technique and the level was normalized to Gapdh expression as 
described under “Experimental Procedures”. Data was expressed as box plots representing fold 
ratio of treatment/control. No significant differences were observed. n=3 per group; Bars, S.E.M., 
































CHAPTER 3: Timing and Duration of Folate Restriction Differentially Impacts Colon 
Carcinogenesis 
Introduction 
Colorectal cancer (CRC) is the second most common reported cancer in western societies 
[101]. The majority of CRC are due to sporadic causes and are not linked to specific mutations 
[102]. Diet plays a crucial role in the risk and development of CRC [103]. Notably, folates, 
contained in vegetables and leafy greens have been associated with a protective effect [19]. Folate 
relevance came to light due to findings that folates reduce NTD, leading to the mandatory 
fortification of cereals and grains [11]. Folates are crucial to purines and pyrimidine synthesis, as 
well as remethylating homocysteine to methionine [104]. Low dietary folates can lead to uracil 
misincorporation in the DNA resulting in double strand breaks, and impaired methylation leading 
to genetic instability and inducing transformation [22], [105].   
Research into the effect of folate restriction on colon carcinogenesis has yielded conflicting 
results. Considerable evidence from the literature suggests that high dietary folates reduced CRC 
risk while low folate induces it [33], [106]. However, there have been many discordant results 
reported in animal studies and from large epidemiological and case control studies [32], [33], [13], 
[5]. These studies raised concerns that the consequences of the mandatory folate fortification could 
lead to detrimental outcomes for a large subset of the population.  
Our lab previously showed that a folate depleted diet in a -pol haploinsufficient mouse 
model provided protection against CRC initiation as seen in reduced incidences of preneoplastic 
lesions (ACF) [87]. Others were able to show that folate restriction protected against intestinal 
tumorigenesis in various lab rodent models [39]–[41], [107]. In this study, we show that long term 




that placing mice on one week of folate restricted diet before initiating carcinogenic (FA/FR) 
treatment produced more ACF compared to animals allowed to acclimate to folate restriction for 
8 weeks (FR). Analysis of the mTOR signaling pathway and DNA methyltransferases revealed a 
divergent effect between long-term folate restriction FR compared to short-term FA/FR. Our 
results indicate that the timing and duration of folate restriction has a differential effect on colon 
tumorigenesis. 
Experimental procedures 
Animals- c57Bl/6 male specific pathogen free mice were purchased from Charles Rivers at 6 weeks 
of age. Animals were maintained in accordance with NIH guidelines for the use and care of 
laboratory animals. The Animal protocol was approved by the Wayne State University Animal 
Investigation Committee. They were fed the standard mouse chow and water ad libitum and were 
maintained on a 12-hr light/dark cycle until the start of the experiment. Mice were anesthetized in 
a CO2 chamber and the abdominal cavity was opened for excising the colon and harvesting the 
liver tissue. Blood was obtained by cardiac puncture, centrifuged, and the serum separated.  The 
harvested liver was flash frozen and stored in liquid nitrogen. 
Diets- At 4 months of age, mice were randomly assigned to two dietary groups and fed AIN93G-
purified isoenergetic diets (Dyets, Inc., Lehigh Valley, PA)[88]. Diets were stored at -20°C. The 
control group received a folate adequate diet (2mg FA/kg diet for 8 weeks). The experimental 
groups: (FA/FR) received (2mg FA/kg diet for 7 weeks then 0 mg folic acid/kg diet for 1 week for 
a total of 8 weeks), and (FR) received a folate deficient diet (0 mg folic acid/kg diet for 8 weeks). 
Control and experimental groups were further divided equally into diets supplemented with either 




Carcinogen treatment- After 8 weeks on the respective diets, mice were treated IP with 1, 2-
dimethylhydrazine HCl (DMH, 30 mg/kg body weight) in 10 mmol/liter of NaHCO3 (Fisher 
Scientific) once a week for 6 weeks. The animals were monitored for signs of toxicity and 
remained on their respective diets for an additional 7 weeks. 
Aberrant crypt foci (ACF) analysis- The excised colons were rinsed with cold phosphate-buffered 
saline, cut longitudinally, and fixed flat overnight in 10% neutral buffered formalin. The fixed 
colons were stained with 2g/liter of methylene blue in phosphate-buffered saline for 5 mins. The 
number of ACF and aberrant crypts per foci were determined by light microscopy at 10X 
magnification in a blinded manner as described previously [36], [87] 
Folate Assay- Serum, liver and colon mucosa were collected upon sacrifice. Folate was measured 
using the Lactobacillus casei microbiological assay of folic acid derivatives as described by Horne 
et. Al[89]. Briefly, growth response of lactobacillus casei to folate availability was measured at 
OD 600 nm. A standard curve was used to calculate folate concentrations. Folate levels are 
expressed as nmol/g.  
Isolation of Whole cell extract- Whole cell extracts were isolated using RIPA buffer. Briefly, 50 
mg of liver tissue was homogenized using RIPA buffer (1% Igepal, 0.5% Sodium deoxycholate, 
0.1% SDS, 1X PBS) combined with HALT protease inhibitor cocktail (Thermo Fisher). Whole 
cell extracts collected were stored at -80°C for further analysis.  
Western Blot Analysis- Protein expression analysis was performed using the V3 western blot 
system from Bio-Rad. 50 μg of protein was loaded onto criterion TGX stain free precast Gels (Bio-
Rad, Hercules, CA). Gels were imaged using chemidoc XRS+ system then wet transferred onto 
nitrocellulose membranes. Membranes and Gels were imaged to verify complete transfer. 




signaling) were used to detect proteins of interest followed by incubation with HRP-conjugated 
secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA). The bands were visualized and 
quantified using chemidoc XRS+ imager and Image lab software (Bio-Rad, Hercules, CA) after 
incubation in SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology, 
Rockford, IL). Data are expressed as adjusted band volume normalized to total lane proteins. 
Phosphorylated forms of proteins were normalized to total and expressed as ratio. 
Gene expression profiling- The mRNA expression levels of various genes were quantified using a 
real-time PCR. Total RNA was extracted from liver tissue using RNeasy extraction kit (Qiagen, 
Valencia, CA). First strand cDNA was synthesized from 1μg RNA using random primers and poly-
A primers. Expression of each gene was quantified using real time PCR with specific primers for 
the gene. The gene transcript was normalized to GAPDH. External standards for all genes were 
prepared by subcloning the amplicons, synthesized using the specific primers into PGEM-T easy 
vector.  
ATP Assay- ADP/ATP ratio was assessed using a luciferase based bioluminescent assay kit 
(Abcam). Briefly, 10 mg of liver tissue was quickly homogenized with nucleotide releasing buffer. 
Using a microplate reader, the homogenate was assayed per protocol to determine ATP induced 
luminescence. Then ADP converting enzyme was added and luminescence was further 
determined. Data are expressed at ADP/ATP ratio.  
NAD/NADH Assay- NAD+/NADH was assayed using a fluorometric microplate reader assay 
(Abcam). 20 mg of liver tissue was homogenized in provided lysis buffer and supernatant was 
collected. Total NAD, NAD+ and NADH were assayed per protocol. Fluorescence was measured 




Statistical Analysis- Statistical significance between means was determined using t-test and 
analysis of variance followed by post tukey test wherever appropriate.  P-values less than 0.05 
were considered statistically significant. 
Results 
Study Design and Rationale 
Folate requirements in mice is not well defined. It is estimated that the minimum 
satisfactory requirement for folic acid based on early mouse studies to be around 0.5 mg/kg diet 
[108]. Modern rodent diets add a minimum of 2 mg/kg diet folic acid to the standard formulations 
[109]. Chow diets contain variable amounts of folic acid ranging from 2-15 mg/kg diet and 
averaging about 8 mg folic acid/kg diet. Mice fed a folate deficient diet experience a quick 
reduction in serum folate levels by as much as 60% after 3 days and is further reduced by 90% 
after 1 week. Maintaining the animals on a folate deficient diet does not yield any additional 
reduction in serum folates after 12 weeks (fig1.3). As a result, rodent studies investigating the 
effect of folate restriction typically do not maintain the animals on folate deficient diets for 
extended periods. A long-term folate restriction aging study conducted by our lab was able to 
maintain the mice on a folate depleted diet for over 32 months with the mice exhibiting better 
health and survival than their folate supplemented counterparts (unpublished data). We 
hypothesized that the animals might be getting trace amounts of folates from the casein-based 
AIN-93G diet as well as a result of gut bacterial fermentation and coprophagy. Since the animals 
did not exhibit any signs of anemia in any of our previous experiments, and no further reduction 
of serum folate levels was observed after the first week, we termed the condition folate restriction 
(FR) rather than folate deficiency (FD). For the purpose of this study, we chose a semi synthetic 




group received a folate adequate diet (2mg FA/kg diet for 8 weeks). The experimental groups: 
(FA/FR) received 2mg FA/kg diet for 7 weeks then 0 mg folic acid/kg diet for 1 week for a total 
of 8 weeks, and (FR) received a folate deficient diet (0 mg folic acid/kg diet for 8 weeks). Control 
and experimental groups were further divided equally into diets supplemented with either 1% of 
the antibiotic succinylsulfathiazole SST (ABx+) or antibiotic free diets (ABx-) (fig 3.1). 
Succinylsulfathiazole (SST), a long-acting sulfonamide, works by inhibiting bacterial folate 
synthesis through competitive inhibition with P-aminobenzoic acid (PABA)[82]. After 8 weeks on 
the respective diets, mice were treated IP with 1,2-dimethylhydrazine (DMH) once a week for 6 
weeks. DMH, an alkylating agent, is a potent colon and liver carcinogen that is extensively used 
to model colon carcinogenesis in rodents [110]–[114]. Animals remained on their respective diets 
until they were sacrificed at 21 weeks. There was no difference in food consumption and animal 
weights between experimental groups and their respective controls at various time points in the 
experiment (fig3.2).  
Effect of folate restriction on folate levels in plasma, liver, and colon. 
Folate levels were measured using the Lactobacillus casei microbiological assay of folic 
acid derivatives as described by Horne et. Al[89]. As expected, serum folate levels decreased 
significantly as a result of both short (FA/FR) and long-term (FR) diets compared to folate 
adequate (FA) diets in both control (CONT) and DMH treated animals (DMH) (fig3.3). The 
reduction of serum levels was not significantly different between FA/FR and FR animals. Animals 
fed diets containing 1% SST (ABx+) showed a greater decrease in serum folate levels when 
compared to mice without the antibiotic (ABx-). DMH had no effect on serum folate levels across 
all groups except for the FR DMH ABx+ group, where folate levels were too low to be assayed. 




and FR conditions compared to FA. The addition of SST further reduced folate levels in the folate 
restricted control groups and more significantly in the DMH treated animals (fig3.4). Analysis of 
the folate levels in the colons of control animals revealed a similar pattern to the liver and serum. 
Folate levels significantly decreased to the same extent in both FA/FR and FR animals compared 
to FA (fig3.5). Animals fed folate deficient diets supplemented with SST experienced a more 
pronounced decrease in folate levels in the colons. Folate data were not collected from DMH 
animals as the colons were stained for ACF screening. A marked decrease of folates was observed 
in the serum of mice fed a folate deficient diet compared to the liver and colon tissues. It was clear 
from our analysis that the addition of the antibiotic SST produced a distinct and significant effect 
on folate levels in all tissues examined owing to its ability to significantly reduce the number of 
folate producing bacteria in the gut. As established previously, since SST perturbs the intestinal 
microbiome and potentially confounds our analysis, we conducted all further mechanistic analysis 
on non-SST supplemented samples. 
Long-term folate restriction protects against preneoplastic lesions initiation 
A quick review of the literature regarding the association between folates and colon 
carcinogenesis reveals an abundance of data linking low folates to adverse outcomes and cancer 
initiation [9], [18], [32], [115]. This view, however, has been challenged by emerging studies 
revealing that the relationship between folates and cancer is much more complex than initially 
perceived [116]. There is mounting evidence that low folate may protect against spontaneous and 
chemically induced cancer [107], [117], [118]. Various epidemiological studies have linked 
elevated folates with a higher incidence of several cancers including colon cancer[20], [35], [119]. 
In this experiment we wanted to assess the effect of the timing and duration of folate restriction on 




of aberrant crypt foci (ACF), a preneoplastic lesion representing the initial stages of cancer 
initiation and development. We established in earlier experiments that folate restriction alone was 
insufficient to induce spontaneous preneoplastic lesions in our mouse model. Weekly DMH 
injections at 30mg/kg body weight for 6 weeks was adequate to induce ACF in c57Bl/6 mice. 7 
weeks after the final injection, the mice were sacrificed, and the colons were stained and scored 
for ACF. Consistent with most published studies, we observed that placing the animals on a folate 
restricted diet for one week (FA/FR) before initiating the carcinogenic insult resulted in 
significantly more ACF compared to animals fed a folate supplemented diet. However, mice 
placed on 8 weeks of a folate (FR) depleted diet were protected as evident in significantly less 
ACF developed compared to (FA/FR) (Fig3.6). We even observed a non-significant decrease in 
the number of ACF when comparing FR to FA. Furthermore, upon sacrifice, we observed major 
pathologies in (FA) DMH animals in the form of large gastric tumors, liver nodules, and atrophied 
and inflamed colons (fig3.7). Our results show that the timing and duration of folate restriction has 
a differential effect on colon cancer initiation. Despite an equal decrease in serum, as well as tissue 
folate levels under short (FA/FR) and long-term (FR) folate restriction, FR conferred protection to 
c57bl/6 mice that acclimated to a folate restricted diet.  
FR modulates the mTOR pathway 
Previously published studies from our lab revealed that combining -pol 
haploinsufficiency with folate restriction reduces ACF formation [87]. This was concurrent with 
decreased proliferation and increased apoptosis in the FR mice. Further studies from our lab 
confirmed that long term folate restricted mice had reduced proliferation in the colon compared to 
FA. Microarray analysis of the colon provided us with important clues that could uncover the 




rapamycin (mTOR) was significantly reduced by FR [87] (table 3.2). We became interested in 
investigating mTOR as a potential driver behind the effects of folate restriction as a major switch 
balancing growth and proliferation with autophagy and apoptosis.  
Western blot analysis revealed reduced activation of mTOR in the liver under both FA/FR 
and FR as evident in reduced phosphorylation of the ser2448 residue (fig3.11). mTOR is 
phosphorylated at ser2448 via the IGF/PI3K/AKT signaling pathway. In DMH treated animals, 
FA/FR and FR show a significantly reduced level of mTOR ser2448 phosphorylation compared to 
FA mice. No difference is observed in the level of ser2448 phosphorylation between FA/FR and 
FR. No difference was observed at the auto phosphorylation site of mTOR, ser2481. This residue 
is considered rapamycin insensitive and is not regulated by the IGF/PI3K/AKT signaling cascade 
[120][121] (fig3.12). To investigate if mTOR is downregulated through inhibition of the IGF 
pathway, we looked at the phosphorylation of PDK1. Phosphorylation of PDK at Ser241 is crucial 
for the activation of the AKT pathway and the downstream mTOR target S6k1 [122]. Surprisingly, 
in DMH treated animals, we observed a significant increase in phosphorylation of PDK1 in FR, 
but not in FA/FR as compared to FA mice. We then looked at REDD1 levels, a marker of hypoxia 
and DNA damage. REDD1 regulates mTOR through activation of the inhibitory TSC1/TSC2 
complex leading to downregulation of mTOR. REDD1 expression was attenuated in both FA/FR 
and FR DMH treated animals as compared to FA DMH (fig3.14). Our finding indicates that mTOR 
inhibition is not mediated through IGF/PI3K/AKT or REDD1 signaling.  
We had established in earlier experiments that folate restriction disrupts energy pools and 
can affect the energy gauge AMPK [123]. AMPK detects changes in the intracellular AMP/ATP 
ratio and is activated under nutrient depletion to inhibit anabolic pathways that consume ATP and 




TSC1/TSC2 complex as well as directly inhibiting mTOR by phosphorylating the critical binding 
subunit raptor [124]. AMPK can neutralize the PI3K activation of mTORC1 as well as enhance 
SIRT1 activity by increasing cellular levels of NAD+ (FIG 2.3). ADP/ATP ratio serves as a proxy 
indicator for energy availability. In both controls and DMH animals we saw a decrease in the 
ADP/ATP ratio in FA/FR compared to FA and FR indicating increased energy availability (fig 
3.15). The ratio was significantly increased in both control and DMH FR animals compared to 
FA/FR indicating that long term folate restriction has a differential effect on energy pools. 
However, looking at AMPK activation through phosphorylation at T172, FA/FR experienced a 
significant increase in AMPK phosphorylation in DMH treated mice compared to controls (fig 
3.16). FR induced increase in AMPK activation did not reach statistical significance (P=0.1). 
Analysis of the NAD+/NADH ratio revealed a non-significant increase (P=0.07) in FR DMH 
compared to FA DMH (fig 3.17).  
SIRT1 mRNA expression was increased in both FA/FR and FR DMH compared to FA 
DMH (fig 3.18). Energy levels, as well as AMPK and SIRT1 activation could potentially explain 
the downregulation of mTORC1 under both FA/FR and FR DMH treated animals despite 
upregulation of the upstream PI3K/PDK/AKT pathway, however, the results could not explain the 
adaptive differential effect that confers protection on long term FR animals.  
mTORC1 regulates protein synthesis and growth through the downstream targets 4E-BP1 
and S6K1. FA/FR DMH resulted in a decrease in 4E-BP1 phosphorylation at T37-46 compared to 
FA DMH, while FR DMH resulted in an additional significant decrease in 4E-BP1 
phosphorylation compared to FA/FR and FA DMH (fig 3.19). Analysis of S6K1 phosphorylation 
revealed a different picture. FA/FR DMH drastically increased activation and phosphorylation of 




regulates multiple processes such as protein synthesis, cellular metabolism, cell cycle progression, 
adipogenesis as well as playing a critical role in cancer [125].  
In summary, we saw that mTOR is downregulated under both FA/R and FR potentially due 
to the activation of AMPK and SIRT1. However, a divergence of effects was observed downstream 
of mTORC1. FR caused a more significant decrease in 4E-BP1 indicating a further reduction in 
cap dependent translation. While FA/FR resulted in a significant increase in S6K1 activation 
potentially reversing the growth inhibition mediated my repressed mTOR and 4E-BP1.  
Effect of FR on methylation 
To assess the impact of a short and long-term folate deficient diet on global DNA 
methylation, we examined the expression levels of the major DNMT’s involved in generating and 
maintaining CpG methylation across the genome. In mammals, DNA methylation is conducted 
mainly by DNMT1, DNMT3A, and DNMT3B. During DNA replication and cell division, 
DNMT1 conserves and maintains the methylation profile. DNMT3A and DNMT3B, expressed 
mainly in undifferentiated cells, are involved in de novo DNA methylation as well as assisting 
DNMT1 in maintaining genomic DNA methylation (fig 3.22) [126], [127]. DNMT1 expression 
decreased significantly in FA/FR DMH compared to FA DMH and FR DMH (fig3.23). There was 
no difference between DNMT1 expression between FR DMH and FA DMH, and a non-significant 
decrease in DNMT1 was observed in FR controls compared to FA and FA/FR controls (fig3.23). 
Similarly, we saw the same trend with DNMT3A mRNA levels significantly decreased in FA/FR 
DMH, but not FR DMH, compared to FA DMH (fig3.24). A non-significant decrease in DNMT3A 
expression was also observed in FR controls vs FA controls (fig 3.24). Expression of DNMT3B 
was equally significantly decreased in both FA/FR DMH and FR DMH compared to FA DMH 




both FA/FR and FA control. Contrary to reported rodent studies[128], long-term folate restriction 
(FR) resulted in decreased DNMT expression (non-significant in DNMT1, P=0.06 in DNMT3A, 
significant in DNMT3B) in our control groups. While long-term folate FR DMH had no effect on 
DNMT1 and DNMT3A, we observed a significant decrease in DNMT3B compared to FA DMH. 
On the other hand, short term folate restriction (FA/FR) did not alter DNMT’s expression in control 
animals, but significantly reduced mRNA expression of all 3 DNMT’s as compared to FA DMH.  
Our results clearly show that FA/FR has a differential effect on the expression of DNMT’s 
compared to FR. These findings could provide us with clues to further investigate the role of DNA 
methylation in the adaptive and protective effect of long term-folate restriction. 
Discussion 
The dichotomy of folic acid 
Folate deficiency has been linked to multiple pathologies including: anemia, psychiatric 
and neurodevelopmental disorders, cardiovascular disease, adverse pregnancy outcomes, low birth 
weight, cancer, and NTD [14], [31], [129], [130]. With the exception of the reduction of NTD, 
evidence of folic acid supplementation having a protective effect against these conditions is 
inconsistent [131]. 
Synthetic Folic acid added to food has a higher bioavailability (70-85%) compared to 
folates naturally occurring in foods (50%) [10], [132]. The widespread consumption of additional 
supplements in the form of vitamins, sports drinks, etc. in addition to fortified foods have caused 
a significant percentage of the population to approach or exceed the tolerable upper daily limit of 
folates [10], [132]–[134]. In Fact, a survey conducted after the folate mandate revealed that 23% 
of the US population, 43% of children under the age of 5 and 38% of elderly persons had high 




(5-methyltetrahydrofolate) as it passes through the intestinal wall thorough a saturable conversion 
mechanism, leading to detectable levels of unmetabolized FA [135], [136]. In Fact, following the 
folate fortification mandate, unmetabolized folic acid was detected in nearly all serum samples 
from US children, adolescents, and adults [137]. Unmetabolized FA can bypass some regulation 
in the one carbon cycle by entering as THF rather than 5-methylTHF leading to potentially 
detrimental effects [138]. Some point to natural folates having a positive differential effect on 
health and disease compared to the synthetic FA [106], [139]. Over the past 2 decades, researchers 
have uncovered a trove of information regarding the effects of folates on health and disease. 
However, these reports have been often contradictory[106], [140], [141] and have ignited a heated 
debate regarding the risks of increasing levels of folates in the population. Of unique importance, 
is understanding how folates both natural and supplemented can modulate cancer risk.  
Folate and cancer 
Folate has a complicated history with cancer. Early publications, following the discovery 
of the role of folates in cancer and the subsequent successful use of anti-folate therapy, established 
the importance of folate in cancer [142], [143]. Accumulating evidence from various experimental, 
clinical and epidemiological studies, suggest that folate deficiency predisposes normal tissues to 
carcinogenesis, while folate supplementation suppresses it [34]. However, high doses leading to 
supraphysiological concentrations can enhance the growth and progression of cancers in normal 
tissues [13], [34]. In the presence of preneoplastic or neoplastic lesions, folate supplementation 
can enhance growth and aggressiveness of many cancers [19], [144]. Animal studies reveal a dual 
modulating effect of folate on colorectal cancer whereby the timing and dosage of folate can have 
contrasting results [33]. Folate deficiency in normal tissues can lead to uracil misincorporation due 




instability [33], [54]. Furthermore, folate deficiency can lead to aberrant DNA methylation due to 
the possible decrease of S-adenosylmethionine [13]. A folate adequate diet is expected to correct 
these aberrations leading to a decrease in cancer risk. However, in preneoplastic or fully 
transformed lesions, folate deficiency can inhibit the growth requirements of a rapidly proliferating 
tissue, leading to decreased tumor growth and progression. At the same time, FA supplementation 
can provide the tumor with nucleotides leading to faster growth [34]. 
Animal studies in various rodent models have linked inadequate folate consumption with 
an increased risk of cancer, specifically CRC [53], [145], [146]. Others have reached an opposite 
conclusion, with many reporting that folate restriction inhibits colorectal tumorigenesis in multiple 
models [40], [107], [147]–[149]. The inconsistencies in the results published have made it difficult 
to draw a conclusion regarding the effect of folate status on colorectal cancer. With the absence of 
a standard model and a multitude of dietary interventions used, it is challenging to draw parallels 
across these studies. Rosati et al [54] published a comprehensive review of models and methods 
used in studying folate and colorectal cancer in rodents. The studies referenced differed in the use 
of animal models, diets, dietary interventions, FA supplementation, antibiotic use, and type of 
caging [54]. Of particular importance, the duration and the type of dietary interventions differed 
considerably. While folate depleted groups received 0 mg/kg folate, control or supplemented 
groups received varying concentrations ranging for 2 mg/kg to 20 mg/kg folate[54]. The duration 
of folate depletion, as well as the use of antibiotics and wire-bottom caging to reduce the microflora 
and coprophagy supplied folates respectively, impacted serum and tissue specific folate levels 
[54]. Data is further confounded by the differential response to folate depletion seen when 




The results of our experiment show unequivocally that within the same mouse genotype, 
the duration of folate restriction has a differential effect on colon carcinogenesis initiation under 
controlled and identical conditions. The inclusion of the antibiotic SST in part of our experimental 
groups allowed us to potentially isolate the effect of the antibiotic on our results and was 
documented in chapter 2. We saw that SST further reduced folate levels significantly in most folate 
restricted groups (fig 3.3, 3.4, 3.5). This effect translated into a non-significant upward trend in 
ACF formation (fig 3.6). Since SST is known to produce a large shift and perturbation in the gut 
microbiome, potentially altering various signaling pathways, we decided to conduct further 
mechanistic analysis on the non-SST supplemented groups. Our mice were housed in normal 
cages, leading to the likelihood of coprophagy. Folate levels form this experiment and previous 
data from our lab confirm that the reduction of folate remains constant after the first week on a 
folate depleted diet (fig 1.2). Since no observation of anemia or growth inhibition was seen even 
when animals remained on the folate depleted diet for several months (unpublished lab data), it is 
safe to assume that this condition is not consistent with a severe folate depletion and therefore 
considered folate restriction. While we saw a significant (90%) reduction in serum folate levels on 
average, the effect on liver and colon was less pronounced, indicating less abundant circulating 
folates and greater enrichment and uptake by tissues. Despite comparable levels of folate in serum 
and tissue of both FA/FR and FR animals, the acclimation period to folate restriction conferred 
protection to these animals. To our knowledge, this constitutes novel findings that has not been 
replicated before. Animal studies that previously attempted to pinpoint the effect of folate 
restriction on initiation of colon carcinogenesis yielded contradictory results due to the differences 
in study design, duration, and timing of folate restriction among other variables [34], [54], [106]. 




after the establishment of the neoplastic lesion [147]. Hanley et al [107] showed that a temporary 
methyl donor depleted diet conferred long-lasting protection against intestinal adenoma by 
inducing changes to the intestinal epithelium. Our data suggest that adapting the animals to folate 
restriction is likely to induce positive and long-lasting changes to the expression profile of various 
tissues. In fact, there is evidence that long term folate restriction can mimic caloric restriction and 
potentially increase lifespan [150], [151]. Methionine restriction, another life extension strategy, 
requires an adaptation period to exhibit an anti-cancer effect (manuscript in preparation) [152], 
[153]. Data from our lab show that long term folate restriction improved survival rate of mice and 
modulated mTOR signaling similar to calorie restriction [123].  
In humans, a large cohort found that individuals consuming the greatest amount of folate 
had a smaller risk of CRC compared the ones consuming the lowest [154]. Other studies could not 
conclude that higher folate status is protective [155], while some reported that low folate is 
protective [117], [156]. Other studies have linked high FA consumption to increases in the rate of 
colon cancer [32], [35]. In a recent large human interventional study, folic acid supplementation 
at 1mg/day had no effect on the recurrence of adenomas[32]. On the contrary, upon follow up, the 
authors reported a significant increase in advanced lesion with high malignant potential in the FA 
groups as well as an increase in overall cancer rates, and no reduction in cardiovascular or stroke 
risk [32]. Similar results were published in other large interventional trials were FA did not 
improve cardiovascular events [157], and an increased trend in total cancer and colorectal cancer 
risk was observed [158]. While several studies indicate that the level of folate levels and intake 
after the fortification efforts may be twice as high as originally anticipated [134], Mason et al. 
hypothesized that the FA fortification could be wholly or partly responsible for the observed 




increased risk of prostate and breast cancer [159]–[161]. In a study of FA supplementation in 
pregnancy, women receiving 5mg FA/day experienced an 70% increased total cancer mortality 
and a doubling of breast cancer mortality compared to women not taking any supplementation 
[144]. Furthermore, Troen et al [162] observed that higher levels of FA in elderly women 
correlated with reduced cytotoxicity of natural killer cells, a critical part of the immune system 
capable of detecting and destroying neoplastic cell clones. However, direct evidence of causality 
between high FA and cancer has not been established [163].  
The discrepant results from various folate studies have ignited a robust debate regarding the risk 
versus benefit of FA supplementation. Some hypothesized that natural folate, not FA is associated 
with the protective effect against CRC  [34], [119], [138]. While others questioned the validity of 
using serum folate versus dietary intake to assess folate exposure [164]. Other modifiers and 
confounding elements such as obesity, smoking, alcohol use, gene polymorphism, and B vitamins 
status could complicate the necessary analysis [138]. Furthermore, parents’ folate status and the 
subsequent effect on epigenetic imprinting can impact the offspring’s cancer risk later in life [138].  
 Attempting to unravel the complex relationship between folate and cancer can prove to be 
quite challenging. Additional layers of complexities are being uncovered as research is progressing 
into the matter and we are thrown into a heated discussion regarding the merits of supplementation. 
Our research provides another piece of evidence supporting the modulating and sometimes 
contradictory effect of folate on health and disease.  
Folate and mTOR 
mTOR is a conserved serine/threonine protein kinase that integrates signals such as growth 
factors, amino acids, energy levels, and nutrient availability to modulate cell growth, proliferation, 




mTORC2. mTORC1 is rapamycin sensitive and is regulated by multiple upstream signals such as 
growth factors, amino acid availability, stress and hypoxia, and energy availability [42], [43]. 
mTORc2 is largely rapamycin insensitive with different regulators and downstream targets and is 
involved in the mTORC1 signaling feedback as well as regulating the actin cytoskeleton [165]. 
mTOR controls protein synthesis and ribosome biogenesis through the downstream targets 4E-
BP1 and P70-S6k1 [166]. mTOR is regulated by and receives input from various upstream 
regulators such as AKT, REDD1, AMPK and signaling pathways such as Wnt and Ras. mTOR 
became the focus of intensive research in recent years as this signaling pathway has been altered 
in various conditions such as cancer, diabetes, and aging [44]. More recently mTOR has been 
found to be modulated by perturbation in one carbon metabolism and more specifically folate 
availability [45]. 
Current research has been unraveling the intimate relationship between the one carbon 
cycle and mTOR. In fact, mTORC1 was found to induce purine synthesis by controlling the 
mitochondrial tetrahydrofolate cycle [47]. mTORC1 was also found to induce the generation of 
SAM [48]. Folate deficiency in mice inhibited both mTORC1 and mTORC2 signaling and 
downregulated amino acid transporters in a pregnant mouse model as well as human trophoblasts 
[51]. Rosario et al. suggests that mTOR senses folate through the proton coupled folate transporter 
by modulating the cell surface expression of folate receptor alpha and reduced folate carrier [49], 
[51], [167]. Folic acid can activate the PI3K/AKT pathway leading to the phosphorylation of 
mTOR and its downstream targets S6K1 and 4E-BP1 [46]. Furthermore, both mTOR and one 
carbon cycle are regulated through energy availability. NAD+/NADH ratio, maintained by 
mitochondrial oxidative phosphorylation, links energy levels and one carbon cycle through 




in C. elegans revealed that low levels of folic acid supplementation inhibit mTOR and IGF1 [169]. 
In vascular smooth muscle cells, FA suppressed mTOR and S6K1 [170]. Others have shown that 
folate deprivation can induce cell cycle arrest in neuronal cells via inhibition of IGF-1 signaling 
[171]. The seemingly contradictory effects suggest that folate can differentially impact mTOR 
depending on the tissue type and conditions.  
In our model, we saw that the timing and duration of folate restriction has a divergent effect 
on the mTOR signaling pathway. Although both FA/FR and FR downregulation of mTOR were 
not mediated by the PI3K/PDK/AKT pathway or REDD1, the perturbation of energy pools and 
subsequent activation of AMPK and SIRT1 provided us with a possible mechanistic justification 
for mTOR decreased phosphorylation. The equal decrease of mTOR activation under both FA/FR 
and FR could not explain the differential effect of these conditions on colon carcinogenesis. 
However, analysis of the downstream targets of mTOR, 4E-BP1 and S6K1, revealed a contrasting 
difference between the two conditions in DMH treated animals. FR decreased 4E-BP more 
significantly than FA/FR indicating a more pronounced inhibition on cap dependent translation, 
reducing cell growth and metabolism. Remarkably, FA/FR induced a significant increase in S6k1 
phosphorylation, while FR had no effect. S6K1 activation could potentially override the inhibition 
on growth and proliferation perpetuated by mTOR [172]–[174]. In fact, mTOR/S6K1 signaling 
plays an important role in colorectal carcinoma [175]. S6K1 is able to phosphorylate targets as 
rpS6 (ribosomal protein S6), eIF4B (eukaryotic translation Initiation Factor 4B) and eEF2K 
(eukaryotic Elongation Factor 2 Kinase), promoting protein synthesis and cell growth [172], [176]. 
S6K1 can also be activated by TOR-insensitive signaling pathways such as PDK1, MAPK and 
SAPK (stress-activated protein kinase) [125], [173]. S6K1 activation contributes to viability, 




The differential effect of short and long-term folate restriction on 4E-BP1 and S6K1 
provided us with crucial evidence to help explain the disparity in the ACF results observed. 
However further investigation and research would be needed to confirm and validate the possibility 
that the protective effect of folate restriction is mediated through the mTOR pathway.  
Folate and methylation 
Folate is essential not only for purine and pyrimidine nucleotide synthesis, but also for 
maintenance of SAM levels, the universal donor of methyl groups to various methylation reactions 
including DNA methylation (fig3.9) [128]. Folate status has a direct and significant effect on DNA 
methylation. Perturbances in the folate pools stemming from low or high folate status can result in 
hypomethylation or hypermethylation leading to epigenetic instability [180]. DNA methylation 
occurs on CpG islands in the promoter regions of genes with the methylation status affecting gene 
expression, chromatin modification, and transcription [181]. A number of disease etiologies 
including cancer are linked to dysfunctional DNA methylation [131]. Methyl donors include: 
folate, B12, betaine, choline and methionine [104]. Critical to maintaining epigenetic imprinting 
to DNA, folates became the focus of fortification efforts to reduce the frequency of neural tube 
defects [182]. Subject to intense scientific debate, the incidence of many diseases including growth 
syndromes, neurological disorders, respiratory disorders, multiple sclerosis, autism, and cancer 
increased post fortification [131], [183]. Conversely, diets deficient in methyl donors have been 
shown to have deleterious effects [184].  
Early animal experiments clearly show that a maternal diet high in methyl donors can alter 
epigenetic imprinting by silencing gene mutations in the agouti and Axin alleles [185], [186]. 
Studies in C57BL/6 mice linked high maternal dietary folate to alteration in the methylome of the 




as behavioral changes [187], [188]. Diets low in folate affected methylation patterns of genes 
associated with cancer, diabetes, autism and schizophrenia in the sperm of male mice [189]. 
Combination of the western high fat diet with FA supplementation in mice can potentially induce 
heritable susceptibility to diseases such as obesity, type 2 diabetes, and insulin resistance in the 
offspring, possibly through epigenetic modification of DNA and histone methylation [131], [190], 
[191]. Human studies linked maternal FA supplementation to changes in global methylation 
patterns as well as the methylation status of several critical genes affecting birth weight, insulin 
resistance, obesity, type 2 diabetes, asthma, and vocabulary development [132], [192]–[197]. 
DNA hypomethylation is considered an early event in carcinogenesis causing increased 
gene expression and DNA strand breaks [181]. In colorectal cancer (CRC), global genomic 
hypomethylation is well documented. Additionally, genomic instability, site specific 
hypermethylation of tumor suppressor, and mismatch repair genes lead to increased mutations 
[128]. Diets deficient in methyl group donors have been shown to upregulate DNA 
methyltransferase DNMT in the rat liver [198], [199]. In contrast, folic acid supplementation has 
been linked to an increase in DNMT activity [200]. Results from recent studies suggest that 
moderate short duration folate deficiency induces DNA hypermethylation in rodent liver, possibly 
due to a compensatory upregulation of DNMT [201]–[203]. Others noted that the genomic DNA 
methylation in the liver returned to baseline after 8 weeks on folate deficient diet [147]. The effect 
of folate restriction on methylation was not consistent across studies. Kim et al. review of the 
literature reported that folate restriction affected DNA methylation differently depending on the 
severity and length of folate restriction, as well as the use of carcinogenic treatments such as DMH 




folate restriction could promote carcinogenesis in adults, however, a transgenerational epigenetic 
effect could modulate cancer risk in the offsprings [138].  
Our results show that long term folate restriction FR produced a more pronounced decrease 
in all DNMT’s expression in control animals compared to FA/FR and FR. However, in the DMH 
treated animals, the expression levels of DNMT1 and DNMT3A in FR animals were equivalent to 
that of FA, while in FA/FR both were significantly reduced. This suggests that animals adapted to 
long term folate restriction and then exposed to DMH mimic FA in the expression of critical 
maintenance methyltransferases. This is consistent with the findings by song et al. [147] noting an 
adaptive rebound of genomic DNA methylation. The differential effect of FR compared to FA/FR 
on DNA methyltransferase expression represents a valid target for further analysis to fully 
characterize the impact on global methylation as well as on gene specific methylation patterns.  
Our research provides yet another evidence of the increasingly complex and puzzling 
effects of folate. This data shows, for the first time in a controlled experiment, that adapting to 
long term folates restriction can provide a protective effect against colon cancer. We show that 
long-term folate restriction impacts critical pathways, such as mTOR and methylation, differently 
than short-term. While more research is needed to unravel the complex dynamics of this observed 
protection, our results provides us with important leads. The significance of these findings is that 
it overturns many of the rigid assumptions we had about the role of folates in CRC, revealing a 
much more complicated picture indeed.  
It is quite clear that the discourse regarding the effects of folate on health and disease will 
not be settled any time soon. In fact, results from the last decades of research regarding the 
relationship between folate and cancer have added to the confusion and complexity surrounding 




delivers a great sense of urgency to pursue vital research and attempt to unravel the mystery. As a 
greater percentage of the population is exposed to elevated levels of folates (both natural and 
synthetic), a condition that may be considered anomalous from an evolutionary perspective, we 
are faced with a difficult conundrum. Do we continue with the efforts to supplement the whole 
population with FA to prevent a limited number of neural tube defects while risking a much larger 
and vulnerable segment of the population? Our incomplete understanding of the subject prevents 
us from providing a definitive answer. Furthermore, it could take decades more for a clear 
consensus to emerge. Further action could be delayed by bureaucracy and policy implementation. 







Figure 3.1: Study design 
Sixty 4 months old C57BL/6 male mice were randomly assigned to 6 groups and fed AIN93G-
purified isoenergetic diets (Dyets, Inc., Lehigh Valley, PA)[88]. The control group (FA) received 
a folate adequate diet (2mg FA/kg diet for 8 weeks) +/- ABx (antibiotic SST). The experimental 
groups: (FA/FR) received (2mg FA/kg diet for 7 weeks then 0 mg folic acid/kg diet for 1 week for 
a total of 8 weeks) +/- ABx (antibiotic SST), and (FR) received a folate deficient diet (0 mg folic 
acid/kg diet for 8 weeks) +/- ABx (antibiotic SST). After 8 weeks on the respective diets, 6-7 mice 
from each group were randomly chosen and treated IP with 1, 2-dimethylhydrazine HCl (DMH, 
30 mg/kg body weight) in 10 mmol/liter of NaHCO3 (Fisher Scientific) once a week for 6 weeks. 
The animals were monitored for signs of toxicity and remained on their respective diets for an 
















Figure 3.2: The effect of short-term and long-term folate restriction with/without antibiotic on 
animal weights in control and DMH treated animals 
Weights of FA, FA/FR, and FR mice +/- ABx (antibiotic SST) at the beginning of the experiment, 
after 8 weeks on respective diets, and at the time of sacrifice (21 weeks). Control n=3, DMH n=6-
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Figure 3.3: The effect of short-term and long-term folate restriction with/without antibiotic on 
serum folate levels in control and DMH treated animals 
Folate levels were analyzed using the Lactobacillus casei microbiological assay of folic acid 
derivatives as described by Horne et. Al[89]. Serum folate levels are expressed as ng/ml. FA: 
Folate adequate, FA/FR: short-term Folate restriction, FR: long-term Folate Restricted, ABx+: diet 
with 1% SST, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. Different letters indicate 










Figure 3.3: The effect of short-term and long-term folate restriction with/without antibiotic on 






Figure 3.4: The effect of short-term and long-term folate restriction with/without antibiotic on liver 
folate levels in control and DMH treated animals 
Folate levels were analyzed using the Lactobacillus casei microbiological assay of folic acid 
derivatives as described by Horne et. Al[89]. Folate levels are expressed as nmol/g. FA: Folate 
adequate, FA/FR: short-term Folate restriction, FR: long-term Folate Restricted, ABx+: diet with 
1% SST, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. Different letters indicate 





Figure 3.4: The effect of short-term and long-term folate restriction with/without antibiotic on liver 






Figure 3.5: The effect of short-term and long-term folate restriction with/without antibiotic on 
colon folate levels in control animals 
Folate levels were analyzed using the Lactobacillus casei microbiological assay of folic acid 
derivatives as described by Horne et. Al[89]. Folate levels are expressed as nmol/g. FA: Folate 
adequate, FA/FR: short-term Folate restriction, FR: long-term Folate Restricted, ABx+: diet with 






Figure 3.5: The effect of short-term and long-term folate restriction with/without antibiotic on 


























Figure 3.6: Long-term folate restriction protects against ACF formation 
Aberrant Crypt Foci (ACF) numbers in the colons of DMH treated mice were determined by light 
microscopy at 10x magnification in a blinded manner as described in material and methods. Image 
I represent a normal colon with no pathologies. Image III shows a preneoplastic aberrant crypt foci 
that displays as a raised area in the center. Highlighted samples refer to animals that exhibited 
large cancerous growths and gross abnormalities in the stomach and liver upon sacrifice. FA: 
Folate adequate, FA/FR: short-term Folate restriction, FR: long-term Folate Restricted, ABx+: diet 
with 1% SST, ABx-: diet without 1% SST. n=6-7. Different letters indicate significant differences 






Figure 3.6: long-term folate restriction protects against ACF formation  




Figure 3.7: Gross abnormalities in FA DMH animals 
The following images refer to cancerous growths and pathologies uncovered in animals in the 






Figure 3.7: Gross abnormalities in FA DMH animals 
 





Figure 3.8: The timing and duration of folate restriction has a differential effect on the occurrence 
of preneoplastic lesions ACF 
Top figure: Folate levels were analyzed using the Lactobacillus casei microbiological assay of 
folic acid derivatives as described by Horne et. Al[89]. Serum folate levels are expressed as ng/ml.  
Bottom figure: Aberrant Crypt Foci (ACF) numbers in the colons of DMH treated mice were 
determined by light microscopy at 10x magnification in a blinded manner. 
 FA: Folate adequate, FA/FR: short-term Folate restriction, FR: long-term Folate Restricted, 
ABx+: diet with 1% SST, ABx-: diet without 1% SST. DMH n=6-7. Different letters indicate 






Figure 3.8: The timing and duration of folate restriction has a differential effect on the occurrence 































Table 3.1: Folate restriction alters plasma amino acids 
Plasma was collected from C57BL/6 mice fed (FA) folate adequate diet (2 mg folic acid/kg diet) 
and (FR) folate restricted diet (0 mg folic acid/kg diet) upon sacrifice. Data obtained from 4 mice 
in each group. Samples were sent to MSU and UC-Davis for HPLC analysis. Amino aicd levels 






Table 3.2: Effect of folate restriction on mTOR pathway genes.  
Total RNA was isolated from the colon mucosa of folate adequate and folate restricted mice using 
the RNeasy Mini Kit (Qiagen, Valencia, CA) per manufacturer's protocol.  RNA samples were 
quantified with NanoDrop ND-1000 (NanoDrop Technologies, Inc, Wilmington, DE) and 260/280 
ratio in the range of 2.0-2.2 was defined as acceptable.  A quality check of the total RNA was 
performed using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA). Microarray 
expression profiling was conducted by Microarray & Bioinformatics Facility Core at Wayne State 
University (Institute of Environmental Health Sciences, Detroit, MI) according to the 
manufacturer’s protocol. Data obtained from 4 mice in each group. Significant differences at P < 





























Figure 3.10: Folate restriction reduces mTOR phosphorylation at the serine 2448 residue 
The level of mTOR protein phosphorylation at serine 2448 was analyzed using western blotting 
as described in materials and methods. Data is expressed as adjusted band volume normalized to 
total lane proteins. Levels of phosphorylated protein were determined first, then the membrane 
lightly stripped and tested for respective total protein. Phosphorylated levels of protein were 
normalized to total and expressed as ratio. FA: Folate adequate diet, FA/FR: short-term Folate 
restricted diet, FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated with 
dimethylhydrazine, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. * Significant 















Figure 3.11: Effect of folate restriction on mTOR auto phosphorylation at the serine 2481 residue 
The level of mTOR protein phosphorylation at serine 2481 was analyzed using western blotting 
as described in materials and methods. Data is expressed as adjusted band volume normalized to 
total lane proteins. Levels of phosphorylated protein were determined first, then the membrane 
lightly stripped and tested for respective total protein. Phosphorylated levels of protein were 
normalized to total and expressed as ratio. FA: Folate adequate diet, FA/FR: short-term Folate 
restricted diet, FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated with 
dimethylhydrazine, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. * Significant 














































Figure 3.12: Effect of folate restriction on PDK1 phosphorylation at the serine 241 residue 
The level of PDK1 phosohoryation was analyzed using western blotting as described in materials 
and methods. Data is expressed as adjusted band volume normalized to total lane proteins. Levels 
of phosphorylated protein were determined first, then the membrane lightly stripped and tested for 
respective total protein. Phosphorylated levels of protein were normalized to total and expressed 
as ratio. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: long-term Folate 
restricted diet, CON: control mice, DMH: mice treated with dimethylhydrazine, ABx-: diet without 















































Figure 3.13: Effect of folate restriction on REDD1 protein expression 
The level of REDD1 protein expression was analyzed using western blotting as described in 
materials and methods. Data is expressed as adjusted band volume normalized to total lane 
proteins. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: long-term Folate 
restricted diet, CON: control mice, DMH: mice treated with dimethylhydrazine, ABx-: diet without 















































Figure 3.14: Effect of folate restriction on energy levels (ADP/ATP ratio) 
ADP/ATP ratio was assessed using a luciferase based bioluminescent assay kit (Abcam). 10 mg 
of liver tissue was quickly homogenized with nucleotide releasing buffer. Using a microplate 
reader, the homogenate was assayed per protocol to determine ATP induced luminescence. Then 
ADP converting enzyme was added and luminescence was further determined. Data are expressed 
at ADP/ATP ratio. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: long-
term Folate restricted diet, CON: control mice, DMH: mice treated with dimethylhydrazine, ABx-



















































Figure 3.15: Effect of folate restriction on AMPK phosphorylation at T172 residue 
The level of AMPK protein phosphorylation at threonine 172 was analyzed using western blotting 
as described in materials and methods. Data is expressed as adjusted band volume normalized to 
total lane proteins. Levels of phosphorylated protein were determined first, then the membrane 
lightly stripped and tested for respective total protein. Phosphorylated levels of protein were 
normalized to total and expressed as ratio. FA: Folate adequate diet, FA/FR: short-term Folate 
restricted diet, FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated with 
dimethylhydrazine, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. * Significant 















































Figure 3.16: Effect of folate restriction on energy levels (NAD+/NADH ratio) 
NAD+/NADH ratio was assayed using a fluorometric microplate reader assay (Abcam). 20 mg of 
liver tissue was homogenized in provided lysis buffer and supernatant was collected. Total NAD, 
NAD+ and NADH were assayed per protocol. Fluorescence was measured at EX/EM=540/590 
nm.  Data is expressed at NAD+ to NADH ratio. FA: Folate adequate diet, FA/FR: short-term 
Folate restricted diet, FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated 
with dimethylhydrazine, ABx-: diet without 1% SST. Control n=3, DMH n=6-7.  * Significant 












































Figure 3.17: Effect of folate restriction on SIRT1 mRNA expression 
Levels of SIRT1 mRNA were analyzed in the liver. Expression of the gene was determined using  
real time PCR technique and the level was normalized to Gapdh expression as described in 
materials and methods. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: 
long-term Folate restricted diet, CON: control mice, DMH: mice treated with dimethylhydrazine, 















































Figure 3.18: Effect of folate restriction on 4E-BP phosphorylation at T37-46 residues 
The level of 4E-BP1 protein phosphorylation at T37-46 was analyzed using western blotting as 
described in materials and methods. Data is expressed as adjusted band volume normalized to total 
lane proteins. Levels of phosphorylated protein were determined first, then the membrane lightly 
stripped and tested for respective total protein. Phosphorylated levels of protein were normalized 
to total and expressed as ratio. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet, 
FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated with 
dimethylhydrazine, ABx-: diet without 1% SST.Control n=3, DMH n=6-7. * Significant 











































Figure 3.19: Effect of folate restriction on P-70 S6K1 phosphorylation  
The level of P-70 S6K1 protein phosphorylation was analyzed using western blotting as described 
in materials and methods. Data is expressed as adjusted band volume normalized to total lane 
proteins. Levels of phosphorylated protein were determined first, then the membrane lightly 
stripped and tested for respective total protein. Phosphorylated levels of protein were normalized 
to total and expressed as ratio. FA: Folate adequate diet, FA/FR: short-term Folate restricted diet, 
FR: long-term Folate restricted diet, CON: control mice, DMH: mice treated with 
dimethylhydrazine, ABx-: diet without 1% SST. Control n=3, DMH n=6-7. * Significant 


































































Figure 3.22: Effect of folate restriction on DNMT1 mRNA expression 
Expression of DNMT1 mRNA was analyzed in the liver tissues. Expression of the gene was 
determined using Real Time PCR technique and the level was normalized to Gapdh expression as 
described in materials and methods. Experiments were conducted in technical triplicates. FA: 
Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: long-term Folate restricted diet, 
CON: control mice, DMH: mice treated with dimethylhydrazine, ABx-: diet without 1% SST. 














































Figure 3.23: Effect of folate restriction on DNMT3a mRNA expression 
Expression of DNMT3a mRNA was analyzed in the liver tissues. Expression of the gene was 
determined using Real Time PCR technique and the level was normalized to Gapdh expression as 
described in materials and methods. Experiments were conducted in technical triplicates. FA: 
Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: long-term Folate restricted diet, 
CON: control mice, DMH: mice treated with dimethylhydrazine, ABx-: diet without 1% SST. 








































Figure 3.24: Effect of folate restriction on DNMT3b mRNA expression 
Expression of DNMT3b mRNA was analyzed in the liver tissues. Expression of the gene was 
determined using Real Time PCR technique and the level was normalized to Gapdh expression as 
described in materials and methods. Experiments were conducted in technical triplicates. FA: 
Folate adequate diet, FA/FR: short-term Folate restricted diet, FR: long-term Folate restricted diet, 
CON: control mice, DMH: mice treated with dimethylhydrazine, ABx-: diet without 1% SST. 
































CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS 
 The relation between folate and cancer is growing increasingly complex as research is 
uncovering new facts that contradict the existing paradigm. For the past several decades the 
collective evidence supported the increased intake of folates to improve health outcomes and 
protect against various cancers, specifically colon cancer [26]. Folate’s role in nucleotide synthesis 
was well known since the 40’s and that knowledge led to the rise of the antifolate class of drugs to 
treat various cancers [142]. Adequate folate is also considered essential for maintaining genetic 
stability and protecting tissues from transformation. However, overly abundant consumption of 
folates can encourage the growth of dysplastic neoplastic lesions [106]. The mandatory 
fortification of grains and cereals with folates to reduce NTD’s since the 90’s led to a substantial 
increase in the population’s folate levels [10].  
Animal studies assessing the risks and benefits of folate supplementation provided 
contradictory findings [54]. Our initial findings uncovering a protective effect of dietary folate 
restriction on colon carcinogenesis in our β-pol haploinsufficient model led us to expand our 
investigation to see if the protection persists in normal mouse genetic background [38]. Our initial 
pilot studies revealed that extended folate restriction, allowing the animals to acclimate, provided 
protection as seen in reduced ACF formation. We then embarked on this current study to further 
characterize and attempt to mechanistically dissect that protective effect. We randomized our 
experimental and control mice in groups with or without the antibiotic succinylsulfathiazole. SST 
is commonly used to reduce folate producing bacteria in the gut of the animals and can therefore 
induce a more severe folate depleted condition. We were also interested in isolating the effect of 
the antibiotic in a folate adequate condition to see if it can modify or confound the suspected 




the mTOR pathway, reducing mTOR phosphorylation and the downstream target 4E-BP1. 
Furthermore, we saw a decrease in IGF1 activation upstream of mTOR as evident from reduced 
PDK1 phosphorylation. Paradoxically, SST increased energy levels leading to decreased 
activation of the mTOR inhibitor AMPK. However, REDD1, an inhibitor of mTOR that responds 
to stress and hypoxia was increased by SST. 
Summary of the effect of SST on the mTOR pathway: 
 
These findings allowed us to characterize the effect of SST on the critical mTOR pathway. 
The observed effects most likely stemmed from the perturbation of intestinal flora leading to the 
disruption of growth signaling and energy metabolism. SST groups were then omitted from further 
mechanistic analysis in the 2nd part of the study.  
 After establishing that an intact microflora is crucial for a sound analysis of the effect of 




were not exposed to SST. The results clearly show that in c57/bl6 mice, carcinogenic treatment 
initiated one week after starting a folate depleted diet caused significantly more ACF than a folate 
depleted diet for 8 weeks when compared to FA control. This effect was observed despite an equal 
reduction in serum, liver and colon folate levels between FA/FR and FR mice. That brings us to 
the conclusion that folate restriction requires an adaptation period to exert a protective effect. 
Analysis of the mTOR pathway revealed that both FA/FR and FR reduced mTORC1 activation. 
However, we observed a paradoxical activation of the IGF1 pathway upstream of mTORC1 though 
increased activation of PDK1. REDD1 expression was decreased in both FA/FR and FR. mTORC1 
downregulation was likely induced by perturbance in energy levels and metabolism as seen by the 
increased expression of AMPK and SIRT1. We observed a differential effect between FR and 
FA/FR downstream of mTOR. 4E-BP1 phosphorylation was significantly reduced in FR compared 
to FA/FR and FA, while S6K1 phosphorylation was significantly increased in FA/FR compared 
to FA and FR. These findings suggest that long term folate restriction FR may potentially inhibit 
growth and metabolism, a condition that is considered protective against cancer initiation and 
progression. While short term folate restriction resulted in a paradoxical increase in S6K1 
activation, potentially overriding the growth inhibition of mTORC1 downregulation. Analysis of 
the DNA methyltransferases revealed that FA/FR resulted in decreased expression of DNMT1 and 
DNMT3a compared to FA, while FR had no effect. The decrease in the activity of 
methyltransferases in FA/FR warrants additional research to fully characterize the impact on 






Summary of the differential effect of timing and duration of folate restriction on mTOR and 
DNA methyltransferases. 
 
It is of utmost importance to continue to investigate the relationship between folate and 
cancer. It would be tempting to accept the opinion of the majority and presume that folate can do 
no harm. However, the magnitude of evidence that points in the other direction has become 
overwhelming. Future studies should focus on attempting to duplicate the results in other lab 
models and genetic backgrounds. Proteomics, metabolomic, and epigenetic studies should be 
conducted to further understand the dynamics and adaptation that link folate to various signaling 
pathways involved in cancer. Establishing accurate and standardized folate requirements for 
animal studies is necessary to draw parallels and compare results. Most importantly, establishing 
the proper human requirements without attempting to generalize and enforce the recommendation 




nutritional requirements and subject to diverse environmental and genetic influences. In the era of 
personalized medicine, we should scrutinize generalized public health policies and personalize 
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Colorectal cancer (CRC) constitutes a major burden on the healthcare system as the second 
most commonly diagnosed cancer in the developed world. Dietary folate is considered an 
important modulator of colorectal cancer. Folate restriction has been implicated in increasing CRC 
incidence by disrupting nucleotide synthesis, Impacting DNA methylation and inducing genetic 
instability. Our research shows that the timing and duration of dietary folate restriction can 
differentially impact Colorectal cancer initiation. Acclimating mice to folate restriction for 8 weeks 
results in a reduced number of preneoplastic lesions compared to mice placed of folate restriction 
for 1 week prior to initiating the carcinogenic treatment. Analysis of the mTOR pathway revealed 
distinct differences in crucial target proteins between the two conditions. Furthermore, we noted 
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